Skip to main content
Premium Trial:

Request an Annual Quote

Caliper's Q4 Sales Rise 29 Percent But Xenogen Buy Swells Losses

NEW YORK (GenomeWeb News) — Caliper Life Sciences today said fourth-quarter revenues increased 29 percent as R&D spending was up 34 percent and losses surged 500 percent.
 
Total receipts for the three months ended Dec. 31, 2006, increased to $34.7 million from $26.9 million year over year.
 
A majority of that revenue came from product sales, which brought in $23.7 million, up 30 percent compared, while services brought in $8.1 million, a 32-percent increase, and licensing and contracts earned $2.9 million, 14 percent over last year.    
 
R&D spending increased to $6.5 million from $4.8 million year over year.
 
Caliper’s net losses increased to $8.9 million from $1.5 million. Caliper said that its acquisition of Xenogen was the most significant factor that contributed to the quarterly loss.
 
Caliper said it had around $11.6 million in cash and equivalents, and $13.3 million in marketable securities as of Dec. 31, 2006.
 
Caliper projects its 2007 revenue will be between $137 million and $143 million, a jump of between 27 and 33 percent from 2006.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.